-+ 0.00%
-+ 0.00%
-+ 0.00%

Teva submits FDA NDA for ecopipam in pediatric Tourette syndrome

PUBT·06/18/2026 20:57:12
Listen to the news
Teva submits FDA NDA for ecopipam in pediatric Tourette syndrome
  • Teva submitted a U.S. FDA NDA for ecopipam to treat pediatric Tourette syndrome.
  • Ecopipam has FDA Orphan Drug and Fast Track designations.
  • Filing backed by Phase 3 data showing delayed relapse versus placebo (p=0.008).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606181656OMX_____CNEWS_EN_GNW1001188570_en) on June 18, 2026, and is solely responsible for the information contained therein.